Early in vivo testing to assess new therapeutic interventions in CF patients

Area of Science:

• Biomedical Science
• Translational Medicine
• Respiratory Medicine

Background:

• Cystic Fibrosis (CF) is a genetic disease with new therapies targeting its fundamental defect.
• Successful clinical trials herald a new era in CF treatment, with numerous drug candidates in development.
• Translating these therapies from research to clinical practice is hindered by a lack of validated biomarker assays for assessing efficacy and safety.

Purpose of the Study:

• To review current in vivo diagnostic methods for assessing CFTR (Cystic Fibrosis Transmembrane conductance Regulator) dysfunction.
• To highlight novel assays for in vivo assessment of CFTR function as a biomarker for drug response in CF clinical trials.
• To discuss the validation criteria for introducing new biomarker assays into clinical trials.

Main Methods:

• Review of existing literature on in vivo tests for CFTR dysfunction.
• Identification and description of emerging biomarker assays.
• Analysis of the requirements for biomarker validation in clinical settings.

Main Results:

• Current biomarker assays for CFTR dysfunction are insufficient for early-phase clinical trials.
• New in vivo methods are being developed to measure CFTR function more accurately.
• There is a growing focus on identifying reliable biological markers for drug response in CF patients.

Conclusions:

• Accurate and reliable in vivo biomarker assays are critical for the successful development of new CF therapies.
• Novel assays assessing CFTR dysfunction are essential for evaluating drug efficacy and safety in early clinical trials.
• Rigorous validation of biomarker assays is necessary before their implementation in CF clinical trials.